Xenograft, Orthotopic & Syngeneic Models

WBI offers xenograft, orthotopic and syngeneic models for assessment of anti-cancer agents.

Xenograft or Orthotopic Model
Species	Athymic nude or SCID mouse; or Athymic nude rat
Group Size	5-20
Dosing	Oral Intravenous Intraperitoneal Subcutaneous Infusion Intranasal Intratracheal
Readouts	Tumor volume
Optional Services	Validation of cell lines for tumor growth MTD determinations (acute or multi-dose) Tumor recoveries at termination; weights and preservation Blood collection PK Organ recoveries & preservation Histology Metastasis observations Custom development

Syngeneic Mouse Models
Manipulation of the immune response through administration of immune therapeutics is an active area of cancer treatments. To evaluate potential treatments, a functional immune system in test animals is essential and is available in syngeneic mouse models. Efficacy of test materials is rapidly evaluated within 2-3 weeks of cell implants and initial dosing with test material.
Cancer Type	Cell Line	Mouse Strain
Breast	4T1	Balb/c
Colorectal	CT26 MC38	Balb/c C57BL/6
Melanoma	B16-F10	C57BL/6
Lung	Lewis Lung	C57BL/6
Pancreas	Pan02	C57BL/6

Cell implantation	Subcutaneous, intravenous
Controls	Anti-PD-1 antibody Anti-PD-L1 antibody Anti-CTLA-4 antibody
Readouts	Tumor volumes measured and reported 3 times weekly with statistical analysis for efficacy. Survival, lung metastasis.
Collections	Tumors at termination Optional: Plasma (or serum) samples during tumor growth and/or at termination; organs (lymph node, spleen, etc.) Dissociation, cryo-conservation and shipment of tumor cells, lymph node cells, spleen cells
Project scheduling	Start-up with cell implants within 2 weeks of order Completion within 4 weeks of order. Optional study extension: Re-implant of cancer cells for evaluation of memory T cells

The following are selected cancer models: